Full-Time

Associate Director Digital Marketing

Rare Hematology

Updated on 9/3/2026

Deadline 10/31/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$148.5k - $214.5k/yr

Cambridge, MA, USA

In Person

Category
Growth & Marketing (1)
Required Skills
LLM
CRM
Social Media
Data Analysis

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • At least 5 years of experience in the pharmaceutical or biopharmaceutical industries, or at advertising agencies serving pharmaceutical clients; both agency and client-side experience are accepted.
  • Experience with brand or digital marketing and customer experience planning.
  • Experience with strategic digital planning and execution.
  • Ability to build cross-functional consensus.
  • In-depth understanding of digital marketing channels and the key benefits each channel provides in driving enhanced customer relationships.
  • Strong understanding of digital marketing, artificial intelligence, trends, and innovations.
  • Experience with agency management.
  • Regulatory review experience.
  • Ability to proactively identify and solve digital marketing challenges.
  • A solution-oriented approach and proficient problem-solving skills.
Responsibilities
  • Own digital and media strategy and execution across healthcare professional and patient audiences, ensuring alignment with brand strategy and business objectives.
  • Lead the evolution of healthcare professional and patient journeys by creating personalized, tailored, and connected experiences across the ecosystem.
  • Continuously optimize the channel and investment mix based on performance, customer behavior, and emerging opportunities.
  • Translate audience insights into integrated omnichannel strategies across media, customer relationship management, web, GEO, social, third-party platforms, and emerging channels.
  • Champion new ways to leverage artificial intelligence across strategy, content, and customer experience.
  • Drive adoption of artificial-intelligence-enabled content development to increase speed, scalability, personalization, and channel optimization.
  • Monitor the evolving generative artificial intelligence and large language model landscape and advance strategies that improve brand and disease-state discoverability, relevance, and accuracy across artificial-intelligence-powered experiences.
  • Partner with internal teams, agencies, GTMC, and enterprise capabilities to pilot and scale innovative artificial intelligence and digital solutions.
  • Champion a customer-first approach by advancing audience segmentation and more relevant content across healthcare professional and patient experiences.
  • Partner across agency, media, PRB, and internal teams to improve how digital content is developed, deployed, and optimized.
  • Own the WAYRILZ patient DSE campaign and end-to-end digital execution, including partnership with the Communications team.
  • Partner with GTMC to establish key performance indicators, measurement frameworks, and ongoing analytics tied to customer behaviors and business objectives.
  • Lead ongoing performance reviews across healthcare professional and patient digital activities and translate insights into clear recommendations for the broader WAYRILZ commercial team.
  • Consistently optimize investment toward the highest-performing audiences, channels, and tactics.
  • Foster a test, learn, and optimize mindset by using data and experimentation to continuously improve marketing effectiveness.
Desired Qualifications
  • Familiarity with brand strengths, opportunities, competitive challenges, and key attributes of the brand lifecycle to support execution of digital engagement activities that drive desired behavior change.
  • A constant focus on enabling the best customer experience in every interaction.
  • Familiarity with actionable digital measurement plans, selecting key performance indicators, and setting goals, targets, and measurement milestones that directly relate to business objectives.
  • Active pursuit of data- and insight-based steering of digital investments, and ability to share insights and shape recommendations based on behavioral and performance data to assess campaign lift and return on investment.
  • Ability to adapt to the changing digital landscape to identify opportunities that deliver the most impact for the brand.
  • Ability to work effectively in a highly matrixed environment with cross-functional teams and agency partners.
  • Proactive self-starter with strong communication and presentation skills.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 17.8% at constant exchange rates, and guidance increased.
  • Pharma launches grew 48.3% in Q2 2026, led by Ayvakit, ALTUVIIIO, Sarclisa.
  • R&D leadership reset under Paulo Fontoura targets faster pipeline conversion from September 2026.

What critics are saying

  • BluePrint layoffs of 229 staff run through June 2027, signaling integration strain.
  • FDA rejected Cenrifki in December 2025; U.S. multiple sclerosis sales stay blocked.
  • Vaccines sales fell 4.7% in Q2 2026, exposing dependence on Dupixent and launches.

What makes Sanofi unique

  • Dupixent topped €5.2 billion in Q2 2026, proving immunology dominance.
  • Sanofi delivered seven Q2 2026 regulatory approvals across immunology, rare disease, oncology, neurology.
  • Cenrifki and Sarclisa Escena show a pipeline converting science into differentiated launches.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.

Associated Press
Jul 10th, 2026
Sanofi's Sarclisa Escena approved in US as first anticancer drug delivered via on-body injector

The US Food and Drug Administration has approved Sanofi's subcutaneous Sarclisa Escena for treating multiple myeloma, making it the first anticancer treatment administered through an on-body injector. The therapy uses Enable Injections' CirCLIQ device, which delivers the drug automatically with a retractable 30g needle. The approval was supported by the IRAKLIA phase 3 study, which demonstrated that Sarclisa Escena delivered via the on-body injector provided similar efficacy and safety compared to intravenous infusion, with significantly shorter treatment time and fewer infusion-related reactions. The study showed a 71.1% objective response rate in patients with relapsed or refractory multiple myeloma. More than 70,000 patients worldwide have been treated with Sarclisa-based regimens. The on-body injector aims to reduce physical burden on healthcare providers whilst offering patients greater convenience during treatment.